FWM
MRNA icon

Focused Wealth Management’s Moderna MRNA Stock Holding History

Focused Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-244
Closed -$24.3K – 656
2023
Q4 		$24.3K Buy
244
+237
+3,386% +$19.9K ﹤0.01% 416
2023
Q3 		$723 Hold
7
– – ﹤0.01% 880
2023
Q2 		$851 Hold
7
– – ﹤0.01% 901
2023
Q1 		$1.07K Hold
7
– – ﹤0.01% 859
2022
Q4 		$1.26K Hold
7
– – ﹤0.01% 837
2022
Q3 		$1K Hold
7
– – ﹤0.01% 871
2022
Q2 		$1K Hold
7
– – ﹤0.01% 847
2022
Q1 		$1K Hold
7
– – ﹤0.01% 903
2021
Q4 		$2K Sell
7
-93
-93% -$27.2K ﹤0.01% 816
2021
Q3 		$38K Buy
+100
New +$36.9K 0.01% 416
2021
Q2 		– Sell
-74
Closed -$10K – 997
2021
Q1 		$10K Buy
+74
New +$10.7K ﹤0.01% 598

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Focused Wealth Management's MRNA Position: Q1 2024 in Review

Focused Wealth Management sold out of Moderna (MRNA) in Q1 2024, closing a stake of 244 shares — an estimated $24.3K sold.

Focused Wealth Management first reported a position in MRNA in Q1 2021 and held it in 11 quarters. The position peaked at $38K in Q3 2021. 902 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

  • Focused Wealth Management reported no remaining Moderna position as of Q1 2024 after selling out during the quarter.
  • Focused Wealth Management sold 244 Moderna shares in Q1 2024, an estimated $24.3K.
  • Focused Wealth Management first reported a position in Moderna in Q1 2021 and held it in 11 quarters.
  • Focused Wealth Management's Moderna position peaked at $38K in Q3 2021.
  • 902 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Focused Wealth Management's 13F filing for Q1 2024, filed 8 May 2024.